Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma (Mel-ImmAdj)

  • STATUS
    Recruiting
  • End date
    Jan 1, 2039
  • participants needed
    1000
  • sponsor
    Hospices Civils de Lyon
Updated on 7 October 2022
metastatic melanoma
nivolumab
ipilimumab
immunomodulators
advanced melanoma
immunologic adjuvant

Summary

Surgical excision is the treatment of choice for stage II, III and resectable stage IV melanoma and is curative in most cases. Given the recent success of immunotherapy for the treatment of patients with advanced metastatic melanoma, the use of immunotherapy has been evaluated in the adjuvant setting for patients at high risk of recurrence. In this context, Nivolumab prolonged Recurrence-Free Survival (RFS) while reducing toxicity compared with Ipilimumab in a phase III clinical trial, and was subsequently FDA-approved in December 2017 for adjuvant treatment of locally advanced melanoma with metastatic lymph node involvement after resection of cutaneous lesions. While a fraction of patients benefit from adjuvant PD-1 immunotherapy, approximately 40% of patients are still relapsing despite this adjuvant treatment, without being able to identify them early and with poor understanding of resistance mechanisms. Additionally, about 15% of the patients will develop serious adverse effects driven by immunotherapy and often discontinuing or even contraindicating the onset of subsequent treatments, hence affecting global patients care. It is therefore of prime importance to identify clinical features able to predict response and toxicities to adjuvant immunotherapy in melanoma.

Details
Condition Melanoma
Treatment Frequency and duration of response to adjuvant immunotherapy according to clinical features, Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features, Duration of relapse-free survival according to clinical features, Duration of overall survival according to clinical features, Overall response rate, Frequency of adverse events according to clinical features
Clinical Study IdentifierNCT05527795
SponsorHospices Civils de Lyon
Last Modified on7 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients diagnosed with stage II, III or IV (resected) melanoma
Treated by surgery and adjuvant immunotherapy between January 1st of 2019 and January 1st of 2029
Gave informed consent to allow the use of biological samples for research purpose
Has read the information sheet regarding this study
With tumor samples available at the biobank center

Exclusion Criteria

Patients under 18 years old
Patients placed under the judicial protection
Opposed to this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note